C.H. Boehringer Sohn AG & Ko. KG is the parent company of Boehringer Ingelheim, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Still headquartered in Ingelheim, it operates globally with 140 affiliates and more than 47,000 employees. The company's key assets of interest are: respiratory diseases, cardiovascular diseases, Parkinson's disease, HIV, thromboembolic diseases, cerebrovascular diseases, oncology, diabetes and hepatitis. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations EFPIA. The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.In October 2012 Boehringer Ingelheim settled a "qui tam" case with the U.S. government for $95 million alleging "off-label" marketing of the drugs Aggrenox, Atrovent, Combivent, and Micardis for uses that weren't approved by the US Food and Drug Administration and were not covered by federal health care programs.In August 2012, Pradaxa claims filed in the federal court were consolidated in a multi-district litigation in the Southern District of Illinois before Chief Judge David R. Herndon. On May 28, 2014,a $650 million settlement was announced on behalf of approximately 3,900 claimants who were injured by the drug Pradaxa made by Boehringer Ingelheim Pharmaceuticals, Inc. The drug is alleged to cause severe bleeding events and/or hemorrhaging to those who were taking the drug. Wikipedia.
News Article | February 16, 2017
RIDGEFIELD, Conn., Feb. 16, 2017 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved SPIRIVA RESPIMAT for the long-term, once-daily maintenance treatment of asthma in people age 6 and older. SPIRIVA RESPIMAT...
News Article | February 27, 2017
HARTFORD, Conn., Feb. 27, 2017 (GLOBE NEWSWIRE) -- The Connecticut Technology Council (CTC) is pleased to announce the 50 women who have been selected as Women of Innovation finalists for the 2017 Women of Innovation awards program. The Women of Innovation® program seeks to celebrate and create a growing network of women in the “trenches” of STEM. Finalists are the scientists, researchers, academics, manufacturers, student leaders, drafters, entrepreneurs, and technicians who create tomorrow’s advancements through their efforts in Connecticut today. The 50 finalists will be recognized at the Women of Innovation® awards gala at the Aqua Turf Club in Plantsville on March 29 from 5 p.m. to 8:30 p.m. A winner in each of the eight award categories will be announced live during the program. The keynote speaker at this year’s ceremony is Adda Birnir, Founder and CEO of Skillcrush, a woman-centric online learning community that helps advance digital skills and creativity, and has been featured on the BBC, Mashable, Fast Company, and Business Insider. Tickets, registration, and details are available online at the CTC website, www.CT.org. The complete list of 2017 Women of Innovation® Finalists is posted below. “For the last twelve years, the Women of Innovation awards ceremony has honored outstanding women who have made significant professional, academic, and community achievements,” said Bruce Carlson, President and CEO of the Connecticut Technology Council. “The 2017 Women of Innovation awards dinner will continue our tradition of celebrating these women and their accomplishments, and marks our expanding program offerings to include and professional growth opportunities to all involved with Women of Innovation, a move aligned with the Connecticut Technology Council’s new strategic initiatives. These initiatives work to fill clear needs in the tech ecosystem here in the state.” The Women of Innovation® program is aligned with CTC’s Talent & Workforce strategic initiative, which is dedicated to bringing a robust tech talent pipeline to Connecticut. Diversity hiring is a significant facet of the Talent & Workforce initiative. Other initiatives include Growth & Innovation, dedicated to serving companies in the growth phase, and the IT & Infrastructure initiative, which focuses on supporting and advocating for the best in tech resources and infrastructure here in Connecticut. Women of Innovation® finalists are nominated by their peers, coworkers, and mentors, and are selected based on their professional experience, history of innovation, ability to think creatively and solve problems, and demonstration of leadership. Students are judged on inventiveness, accomplishment in science and technology, independent research, and academic achievement. This year’s 50 finalists includes researchers, educators, engineers, managers, students and entrepreneurs who work or study biotech, pharmaceuticals, software, computer hardware, advanced materials, medical devices, IT, or associated fields. High school, undergraduate and graduate students who have demonstrated extraordinary and unique achievements in their technology disciplines are also among the finalists. The winner in the Youth Innovation and Leadership category will receive a $4,000 scholarship from Medtronic, one of the program’s presenting sponsors. Women of Innovation® is presented in conjunction with the following companies: Day Pitney LLP, Medtronic Inc, and United Technologies Corporation. The program is supported by Pfizer Inc. and Pitney Bowes Inc., with contributions from Premier Limousine and Marcum LLP. For questions regarding the program or awards dinner please contact Paige Rasid at 860.289.0878 x335. Below is a list of the 2017 Women of Innovation® with their affiliated organizations and town of employment or hometown: Jennifer McFadden, Yale University, Madison Summer McGee, University of New Haven, West Haven Janice Naegele, Wesleyan University, Middletown Michelle Bellinger, Academy of Aerospace & Engineering, West Hartford Nivea Torres, Connecticut Technical High School System (CTHSS), Middletown Jun Chen, University of Connecticut, School of Engineering, Storrs Deborah Dorcemus, University of Connecticut, Danbury Erin Duffy, Yale University, West Haven Wafa Elmannai, University of Bridgeport, Bridgeport Manisha Mishra, University of Connecticut, Storrs Jessica Angier, Hybrid Intelligence, Inc., Shelton Jessica Bailey, Greenworks Lending, Darien Wendy Davis, GestVision, Inc., Guilford Marcia Fournier, Bioarray Genetics, Farmington Ellen Matloff, My Gene Counsel, LLC, North Haven Melissa Baran, Sikorsky Aircraft, A Lockheed Martin Company, Stratford Vicki Conant, Sikorsky Aircraft, A Lockheed Martin Company, Stratford Jennifer Graham, Sikorsky Aircraft, A Lockheed Martin Company, Stratford Karen Iannella, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Jacqueline Jones, PhD., Medtronic, Branford Bhagyashree Khunte, Pfizer, Inc., Groton Jeanne Larsen, UTC Aerospace Systems, Windsor Locks Ping Liu, Sikorsky Aircraft, A Lockheed Martin Company, Stratford Devu Manikantan Shila, Ph.D, United Technologies Research Center, East Hartford Jennifer McLaurin, UTC Aerospace Systems, Windsor Locks Lindsay O'Donnell, Sikorsky Aircraft, A Lockheed Martin Company, Naugatuck Kremena Simitchieva, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Susan Baserga, Yale School of Medicine, New Haven Jinbo Bi, University of Connecticut, Storrs Alison Gotkin, United Technologies Research Center, East Hartford Nancy Petry, UConn Health, Farmington Danyel Racenet, Medtronic, North Haven Kelly Valentine, Medtronic, North Haven Christine Wetzel, 3M, Meriden Margaret Bailey, Sonalysts, Waterford Jeanine Gouin, Milone & MacBroom, Inc., Cheshire Chun Li, Diameter Health, Farmington Mary Ellen Mateleska, Mystic Aquarium, a division of Sea Research Foundation, Mystic Feliciatas Thurmayr, MD, PhD., Quality Health Ideas, Inc., Suffield Meghan West, CNC Software Inc /Mastercam, Tolland The Connecticut Technology Council is a statewide association of technology oriented companies and institutions, providing leadership in areas of policy advocacy, community building and assistance for growing companies. Speaking for over 2,000 companies that employ some 200,000 residents, the Connecticut Technology Council seeks to provide a strong and urgent voice in support of the creation of a culture of innovation. This includes working to position Connecticut as a leader in idea creation, workforce preparation, entrepreneurial aptitude, early stage risk capital availability and providing on-going support and mentoring to high potential firms. For more information, visit www.ct.org.
News Article | January 21, 2017
Zika Virus - What You Should Know The adverse health effects of synthetic chemicals usually found in common household or agricultural products like insecticides are being revealed. A new research from the University at Buffalo adds another reason why it's best to steer clear from these types of chemicals at all cost. Insecticides are actually a type of pesticide specific to insects. They are frequently used in agriculture, industrial, public health, and household setting to ward off or totally eliminate undesirable bugs, such as roaches, mosquitoes, and termites. Other forms of pesticides include herbicides (non-beneficial plants or weeds), fungicides (molds, mildew, and rust), rodenticides (rats, mice, gophers), algaecides (algae), disinfectants and antimicrobials (bacteria and viruses). Insecticides are available in various formulations and ways of applications. Some of these include sprays, baits, and slow-release diffusion. According to EPA, the most commonly used insecticides are the organophosphates, pyrethroids, and carbamates. Based on a 2001 report by the U.S. Department of Agriculture (USDA) insecticides accounted for 12 percent of total pesticides applied to the surveyed crops. Corn and cotton, on the other hand, account for the largest shares of insecticide use in the United States. A study published in Chemical Research in Toxicology discovered alarming health consequences humans are at risk of when exposed to active chemical ingredients in insecticides. "No one was thinking that the melatonin system was affected by these compounds, but that's what our research shows," Marina Popovska-Gorevski, co-author, now a scientist with Boehringer Ingelheim Pharmaceuticals, stated. "We found that both insecticides are structurally similar to melatonin and that both showed affinity for the melatonin, MT2 receptors, that can potentially affect glucose homeostasis and insulin secretion," Popovska-Gorevski said. "That means that exposure to them could put people at higher risk for diabetes and also affect sleeping patterns," she added. Funded by a grant from the National Institute of Environmental Health Sciences, under the National Institutes of Health (NIH), the study centers on two chemicals: carbaryl (which despite being banned in many countries, is currently the third most extensively used insecticide in the United States), and carbofuran (which is considered as the most lethal carbamate insecticide prohibited from all forms of applications on food crops for human consumption since 2009). Pesticides are everywhere, but with a conscious effort, it's possible to reduce risks of being exposed to them. Go for green and chemical-free alternatives when addressing pest issues at home or garden. Opt for organic fruits and vegetables. Diet plays a big part, too, since most crops in the country are notorious for being heavily sprayed with chemical fertilizers and pesticides. © 2017 Tech Times, All rights reserved. Do not reproduce without permission.
News Article | February 22, 2017
ALEXANDRIA, Va., February 22, 2017 - CancerLinQ LLC and the American Society for Radiation Oncology (ASTRO) are partnering to bring radiation oncology expertise to CancerLinQ and improve the care of cancer patients nationwide. ASTRO will provide guidance for the development of the CancerLinQ platform to ensure that the system captures more relevant patient data to drive actionable decision-making in cancer care, as well as to advance public policy and population health issues. ASTRO also will use insights from CancerLinQ Discovery to improve the care of patients receiving radiation therapy. Between half and two-thirds of all cancer patients receive radiation therapy, also known as radiotherapy, to cure cancer, control its spread and relieve symptoms such as pain. At present, however, important details about radiation dose and treatment schedule are often absent from the electronic health record systems used in many oncology practices. Through the partnership, experts will develop specialized indicators for radiation-related treatment outcomes and quality that can be incorporated into the CancerLinQ platform. Inclusion of these metrics will provide a much more complete and accurate characterization of the cancer care that patients are receiving, particularly for the many situations where radiation and chemotherapy are combined. "The addition of the nation's radiation oncologists is essential to ensuring CancerLinQ's capacity to improve patient care and can help both organizations achieve outcomes that are larger and more impactful than what either one could have achieved alone," said Kevin Fitzpatrick, Chief Executive Officer of CancerLinQ LLC. "With ASTRO, we are bringing the expertise of the nation's leading physicians who specialize in treating more than one million patients each year with radiation therapy." The partnership reflects CancerLinQ's goal to create a system that encompasses all of cancer care by bringing together expertise from throughout the cancer community, as well as ASTRO's mission to improve patient outcomes through research and education. "With the number of cancer patients rising each year, collaboration across the spectrum of cancer care has to be our reality rather than our goal," said Laura Thevenot, Chief Executive Officer of ASTRO. "By combining ASTRO's domain-specific knowledge with CancerLinQ's broad reach, we can help physicians and their patients be more informed as they navigate complex treatment decisions." As an official partnering organization of CancerLinQ, ASTRO will support professional member participation in the program, advocate for streamlined data integration between leading oncology electronic health systems, and strengthen CancerLinQ's role as a go-to resource for the healthcare community. ASTRO will have access to CancerLinQ Discovery, which generates specially curated sets of de-identified clinical data from the CancerLinQ platform for oncologists, researchers and analysts to create new clinical knowledge and improve patient outcomes. In addition, ASTRO will become a founding member of the CancerLinQ Oncology Leadership Council, a body of thought leaders and oncology-affiliated experts that advises the CancerLinQ Board of Governors. CancerLinQ is a powerful database--created by oncologists for oncologists--made up of vast amounts of usable, searchable, real-world cancer information. This big data initiative will allow users to see trends among millions of patients by analyzing cancer patient medical records, uncovering patterns that can improve patient care, and enabling doctors to compare their care against that of their peers and recommended guidelines. In addition to the radiation oncologists, CancerLinQ LLC--a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO)--is forging important strategic alliances with national leaders and organizations that play important roles across the entire care continuum that support high-quality care for patients, including professionals representing the entirety of the care team, government agencies, academic research institutions, life sciences, technology experts and advocacy organizations. CancerLinQ is supported in part through the Conquer Cancer Foundation, whose generous donors have helped make the system possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America; Chan Soon-Shiong Family Foundation; Genentech BioOncology; HELSINN; Janssen Oncology; Lilly; Raj Mantena, RPh; Novartis Oncology; Pfizer Oncology; Thomas G. Roberts, Jr., MD, and Susan M. DaSilva; and Susan G. Komen. CancerLinQ and CancerLinQ Discovery are projects of CancerLinQ LLC. For more information on how to participate or partner with CancerLinQ, please visit CancerLinQ.org. CancerLinQ LLC is a subsidiary of American Society of Clinical Oncology, Inc. established for the development and operation of the CancerLinQ initiative. CancerLinQ is a health information technology platform aimed at enhancing and improving the understanding and treatment of cancer. To learn more, visit http://www. . ASTRO is the premier radiation oncology society in the world, with more than 11,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology * Biology * Physics and Practical Radiation Oncology and Advances in Radiation Oncology; developed and maintains an extensive patient website, http://www. ; and created the Radiation Oncology Institute, a non-profit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit http://www. . Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO) is committed to making a world of difference in cancer care. As the world's leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at http://www. , explore patient education resources at http://www. , and follow us on Facebook, Twitter, LinkedIn, and YouTube.
Michel M.C.,Boehringer Ingelheim |
Michel M.C.,Johannes Gutenberg University Mainz |
Foster C.,Boehringer Ingelheim Pharmaceuticals |
Brunner H.R.,University of Lausanne |
Liu L.,Fu Wai Hospital
Pharmacological Reviews | Year: 2013
Angiotensin II type 1 receptor antagonists (ARBs) have become an important drug class in the treatment of hypertension and heart failure and the protection from diabetic nephropathy. Eight ARBs are clinically available [azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan]. Azilsartan (in some countries), candesartan, and olmesartan are orally administered as prodrugs, whereas the blocking action of some ismediated through active metabolites. On the basis of their chemical structures, ARBs use different binding pockets in the receptor, which are associated with differences in dissociation times and, in most cases, apparently insurmountable antagonism. The physicochemical differences between ARBs also manifest in different tissue penetration, including passage through the blood-brain barrier. Differences in binding mode and tissue penetration are also associated with differences in pharmacokinetic profile, particularly duration of action. Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly telmisartan, are partial agonists at peroxisome proliferator-activated receptor-g. All of these properties are comprehensively reviewed in this article. Although there is general consensus that a continuous receptor blockade over a 24-hour period is desirable, the clinical relevance of other pharmacological differences between individual ARBs remains to be assessed. © 2013 by The American Society for Pharmacology and Experimental Therapeutics.
Boehringer Ingelheim Pharmaceuticals | Date: 2011-03-23
Methods for the diagnosis of inflammatory bowel diseases and the identification of agents useful in the treatment of such diseases based upon the agents effect on reducing Pim-2 expression.
Boehringer Ingelheim Pharmaceuticals | Date: 2012-03-29
The present invention relates to mouse and human J12 polynucleotides, polypeptide and anti J12 antibody molecules. The J12 is a cytokine that is preferentially expressed in Th2 cells. The polypeptides and/or antibodies described herein can be used in methods for detection and treatment of certain autoimmune and inflammatory diseases including asthma.
Boehringer Ingelheim Pharmaceuticals | Date: 2011-12-19
A method for modulating NF-B dependent gene transcription in a cell comprised of modulating IKK and IKK protein and protein activity in the cell. The present invention also provides siRNA compositions and methods thereof for modulating NF-B dependent gene transcription.
Boehringer Ingelheim Pharmaceuticals | Date: 2011-07-27
An automated data processing method for obtaining clinical data for safety, efficacy, and adverse event assessments pertaining to a therapy prescribed for the treatment of a malady, comprising the step of receiving at a location remote from a plurality of patients outcome digital information pertaining to the outcome of therapies performed on said patients, and for the efficient delivery of medications to a patient ordered pursuant to an electronic prescription from a dispensary optimized for delivery of the medication.
News Article | February 24, 2017
RIDGEFIELD, Conn., Feb. 24, 2017 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a real-world analysis showing that Pradaxa® (dabigatran etexilate mesylate) was associated with an improvement in safety and efficacy outcomes compared to warfarin in...